OBJECTIVE: To examine the association between baseline testosterone levels and changes in visceral adiposity in Japanese-American men. DESIGN: Prospective observational study. SUBJECTS: Second-generation Japanese-American males enrolled in a community-based population study. MEASUREMENTS: At baseline, 110 men received a 75 g oral glucose tolerance test (OGTT), and an assessment of body mass index (BMI); visceral adiposity measured as intra-abdominal fat area (IAF) using computed tomography (CT); fasting insulin and C-peptide levels; and total testosterone levels. IAF was re-measured after 7.5 y. Subcutaneous fat areas were also measured by CT in the abdomen, thorax and thigh. The total fat (TF) was calculated as the sum of IAF and total subcutanous fat areas (SCF). RESULTS: After 7.5 y, IAF increased by a mean of 8.0 cm 2 (95% CI: 0.8, 15.3). Baseline total testosterone was signi®cantly correlated with change in IAF (r À0.26, P 0.006), but not to any appreciable degree with change in BMI, TF, or SCF. In a linear regression model with change in IAF as the dependent variable, baseline testosterone was signi®cantly related to this outcome while adjusting for baseline IAF, SCF, BMI, age, diabetes mellitus status (OGTT by the WHO diagnostic criteria) and fasting C-peptide (regression coef®cient for baseline testosterone [nmolal] À107.13, P 0.003). CONCLUSIONS: In this Japanese-American male cohort, lower baseline total testosterone independently predicts an increase in IAF. This would suggest that by predisposing to an increase in visceral adiposity, low levels of testosterone may increase the risk of type 2 diabetes mellitus.
Introduction
Obesity is a major risk factor in the development of type 2 diabetes millitus (DM), hypertension and cardiovascular disease (CVD). 1 ± 3 In particular, central obesity with a preponderance of intra-abdominal fat (IAF) accumulation correlates more strongly with the estimates of disease risk, 4, 5 and is known to be more diabetogenic 6, 7 than subcutaneous fat accumulation. Visceral fat or IAF area also contributes signi®cantly more to the variances in cardiovascular risk pro®le than waist-to-hip ratio (WHR) measurement, 5 which does not differentiate between subcutaneousand intra-abdominal fat. Assessing body fat distribution by computed tomography (CT), which gives accurate estimates of IAF area, 8 would permit examination of the contribution of visceral fat to glucose homeostasis and lipid metabolism. In fact, CT-measured IAF areas were found to be signi®cantly increased at baseline in Japanese-American subjects who later developed type 2 DM, compared with those who remained non-diabetic. 9 Men are at higher risk than women of developing coronary heart disease at an earlier age and tend to gain weight predominantly in the abdomen. Hyperandrogenicity is further implicated in the regulation of body fat deposition in women with central obesity and insulin resistance. 10, 11 However, in contrast to the ®ndings in women, several studies have found that greater central obesity (based on WHR) is actually associated with lower levels of androgens in men. 12 ± 18 Numerous studies have also clearly documented a cross-sectional association between lower testosterone concentrations in men and higher circulating insulin and insulin resistance. 14,15,19 ± 23 In fact, an earlier study showed that low-dose testosterone administration in obese men decreased CT-measured visceral fat mass without changing subcutaneous fat or lean body mass and also reduced insulin resistance. 24 Diabetic men have also been found to have relatively low testosterone levels. 25 Bjo Èrntorp has proposed that relative hypogonadism might be the primary event preceding the develop-ment of central obesity and insulin resistance in men. Low testosterone levels have been shown to predict the risk of developing diabetes in Multiple Risk Factor Intervention Trial (MRFIT) men 16 and in older Swedish men, 17 but this association was independent of WHR in the latter population. CT assessment of abdominal fat was not performed in either study. The question remains in men as to which abdominal fat compartment (visceral or intra-abdominal vs subcutaneous) is principally associated with testosterone, and whether low testosterone level precedes or follows gain in visceral adiposity.
We therefore tested the hypothesis that low baseline testosterone levels were associated with IAF accumulation in Japanese-American men followed prospectively for 7.5 y in King County, Washington State. The relationship between testosterone levels and indices of glucose metabolism at baseline were also examined since Japanese Americans are known to have high prevalence of type 2DM. 26 
Methods

Study subjects
The study population comprised second-generation Japanese-American (Nisei) men enrolled in the Japanese-American Community Diabetes Study (JACDS). Details about the selection and recruitment of the sample population have been described previously. 27 Brie¯y, subjects were chosen from among volunteers and were representative of the Japanese Americans in King County, WA, in age distribution, residence and parental immigration patterns. The enrollment of 229 Nisei men started in 1983 and all follow-ups were completed in 1994. Serum total testosterone was ®rst measured at 2.5 y of follow-up (`baseline' for this analysis) when those men who were not diabetic at study entry returned for an oral glucose tolerance test (OGTT), CT measurement of body fat distribution, and measurements of serum testosterone, plasma insulin and C-peptide. All measurements except testosterone were repeated 7.5 y later. Of the original cohort of 229 Nisei men, 151 were not diabetic at entry, 135 had baseline CT measurement of IAF at 2.5 y, and 113 returned for the 7.5 y follow-up and repeat IAF assessment. Of these, 110 subjects had a baseline total testosterone measurement and constituted the study sample for this analysis.
Data collection
Baseline and follow-up evaluations were performed at the General Clinical Research Center at the University of Washington Medical Center. The research protocol was reviewed and approved by the institutional human subjects review committee and signed informed consent was obtained from all participants. A 75 g OGTT was used to classify all subjects as having normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or type 2 DM, based on the WHO diagnostic criteria. 28 Serum glucose was assayed by an automated glucose oxidase method at 0, 30, 60, 90, 120 and 180 min during the OGTT. Plasma insulin and Cpeptide levels were determined by radio immunoassay performed at the Diabetes Endocrinology Research Center at times 0, 30, 60, 90, 120, and 180 min during the OGTT. Serum total testosterone level was measured in the Department of Laboratory Medicine at the University of Washington Medical Center using a commercially prepared radio immunoassay kit (Immuchem Corp, Carson, CA). The sensitivity of the assay was 0.69 and 51.9 nmola1 for the lower and upper limits, respectively. The reference range was 9.69 ± 35 nmola1 in adult males and the interassay coef®cient of variation was between 7.5 ± 8.8%
Mesurement of body mass index and body fat distribution
Body mass index (BMI) was computed as weight in kilograms divided by height in meters squared (kgam 2 ). Single computed tomography (CT) scans of 10 mm slice thickness were obtained of the thorax, abdomen and right thigh, as previously described. 6 Adipose tissue was within the attenuation range of À250 and À50 Houns®eld Units (HU). Visceral obesity was measured as intra-abdominal fat (IAF) area in centimeters squared (cm 2 ) at the level of the umbilicus (approximately L4 ± 5). Subcutaneous fat areas were also measured by CT scan in the abdomen, thorax and thigh. Total fat (TF) was calculated as the sum of IAF and total subcutaneous fat (SCF) areas.
Statistical analysis
Base 10 log transformed testosterone levels were calculated to correct for the slight positive kurtosis of the non-transformed total testosterone values. The logtransformed testosterone levels were used in all other statistical computations. Means of differences between baseline and 7.5 y follow-up were compared using paired t-test or Wilcoxon paired signed-ranks test in cases where the assumption of normality was not satis®ed. Pearson correlation coef®cients were calculated for univariate comparisons of continuous variables, except in cases of skewed distributions, when Spearman rank coef®cients were calculated. Statistical signi®cance of a linear trend was computed using ANOVA. Multiple linear regression analysis was used to model the change in IAF as a function of variables of interest and the presence of interaction between covariates in the models. Analysis of residuals was performed to examine model ®t and adherence to regression assumptions.
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Results
Baseline characteristics of study subjects Table 1 shows the baseline characteristics (mean AE s.d.) of the 110 men as a group and also by their baseline OGTT status. The IGT and DM groups had signi®cantly higher levels of fasting insulin and Cpeptide. Moreover, baseline BMI, TF, IAF and SCF were also signi®cantly greater in the IGT and DM groups. Baseline testosterone levels were lower in the DM group, at a borderline level of signi®cance.
Changes in BMI and fat distribution over 7.5 y
Over the follow-up period of 7.5 y, the BMI of most subjects (68%) increased. This was also re¯ected by a gain in TF as well. Although the quantities of fat areas (cm 2 ) increased to a similar degree for both IAF and SCF (see Table 2 ), the proportional increase was greater for IAF (6.7%) than for SCF (2.6%). Statistically, IAF also increased to a signi®cant degree during follow-up, while SCF did not ( Table 2) .
Correlation of testosterone with changes in BMI and fat distribution
Change in IAF over 7.5 y (DIAF) paralleled change in BMI (DBMI; r 0.53, P`0.0001), change in TF (DTF; r 0.73, P`0.0001), and change in SCF (DSCF; r 0.36, P`0.0001). However, only DIAF correlated signi®cantly with baseline testosterone (r À0.26, P 0.006; Figure 1 ). No signi®cant association was detected for baseline testosterone vs DBMI (r À0.08), DTF (r À0.10), or DSCF (r À0.04).
Categorical trend
When DIAF was grouped into quartiles (see Table 3 ), a signi®cant linear trend (P 0.029) was detected across the means of the baseline testosterone levels, adjusted for baseline BMI, IAF, SCF, age and OGTT status. The fourth quartile, which had the greatest gain in mean intra-abdominal fat area, had the lowest logtransformed testosterone level (1.17 nmola1). Conversely, the subjects in the ®rst quartile, all of whom had lost intra-abdominal fat over the 7.5 y, had a relatively high mean testosterone level (1.23 nmola1) at baseline. On the other hand, no signi®cant linear trends were detected in baseline testosterone levels by quartiles of DTF, DSCF or DBMI (data not shown).
Correlation between baseline testosterone and insulin and C-peptide
Low baseline testosterone level correlated signi®-cantly with baseline levels of fasting C-peptide (r À0.34, P`0.0001) and fasting insulin (r À0.26, P`0.01). The strength of the association between fasting insulin and testosterone was diminished (P b 0.05) after adjusting for baseline IAF, while the C-peptide level remained signi®cantly correlated (P 0.001) with testosterone. Figure 1 Correlation between intra-abdominal fat change and baseline testosterone.
Low
Linear regression was used to examine the relationship between DIAF and baseline testosterone. A multivariate model was used with adjustment for potential confounders, including baseline IAF and SCF areas, BMI, age, OGTT status (NGT, IGT and DM), and fasting C-peptide level. The main variable of interest, baseline testosterone, was a signi®cant predictor of DIAF. The negative sign of its regression coef®cient indicates an inverse association between baseline testosterone level and change in IAF. Additionally, no signi®cant interactions were found among any pair of covariates. Table 4 shows the coef®cients of the independent variables and the corresponding signi®cance levels. Baseline SCF, as a potential confounder, was also associated with change in IAF area over 7.5 y (P 0.046).
Discussion
This study is the ®rst, to our knowledge, to demonstrate a strong inverse relationship between the baseline level of total testosterone and accumulation of CT-measured IAF area over time. Most other observational studies have reported the relationship between testosterone and central obesity using crosssectional data or WHR, instead of CT quanti®ed visceral fat area. Our results suggest that baseline serum testosterone level is related to the degree of IAF accumulation over 7.5 y of follow-up in a group of Japanese-American men. Furthermore, if we compared two hypothetical groups of men with the same baseline age, BMI, IAF and SCF areas, DM status and fasting C-peptide level, but with one group having total testosterone level at the upper limit of thè normal' range (about 35 nmola1) and the other group at the lower limit (about 10 nmola1), the group with lower baseline testosterone level would gain an additional 60 cm 2 of IAF in 7.5 y (based on regression coef®cients in Table 4 ). If those observations are correct, then even a`normal' plasma testosterone level at the lower end may predispose to greater visceral adiposity and consequently, higher risk for diabetes mellitus and coronary heart disease. The distribution pattern of adipose tissue varies by gender. The android pattern, seen more often in men, is characterized by fat deposition in the abdomen, whereas femoral ± gluteal fat accumulation, seen more often in women, characterizes the gynoid pattern. The common belief, therefore, is that maleness with excess androgens is associated with central obesity. While hyperandrogenicity is a signi®cant contributor to increased central adiposity in women, 11, 29, 30 it is clearly not so in men. Instead, testosterone levels are lower in men with increased abdominal girth or WHR compared to age-matched, non-obese men. 12,13,31 ± 33 To better quantify the contribution of IAF to this observation, a method such as CT is required, because of the imperfection correlation between surface circumference measurements and visceral fat mass. 34 IAF depots are more metabolically active with more rapid lipid turnover 35 and greater lipid uptake 36 than subcutaneous fat depots. Omental adipocytes have been shown to be more lipolytic in response to catecholamines 37, 38 compared to subcutaneous adipocytes, possibly due to differences in he number and activity of b and a adrenoceptors in the two adipose tissues. 39 Testosterone is shown to promote lipolysis by enhancing catecholamine-mediated lipid mobilization in rat adipocytes. 40 Visceral fat tissue may be more sensitive to the testosterone effect seen in vitro. In a randomized study, a modest dose of testosterone replacement to middle-aged centrally obese men reduced CT-measured visceral fat after 8 months, whereas no signi®cant change in subcutaneous fat was detected. 24 Additionally, testo- Low testosterone in visceral fat accumulation EC Tsai et al sterone administration resulted in a greater inhibition of lipoprotein lipase (LPL), the main enzyme regulating lipid uptake and accumulation into adipocytes, in the abdominal subcutaneous fat than in the femoral fat. 41, 42 Although it has not been conclusively demonstrated, it has been inferred that testosterone inhibits LPL to a similar or greater degree in visceral fat as in abdominal subcutaneous fat. In another study, a onetime high-dose testosterone administration to apparently healthy men decreased lipid uptake in intraabdominal fat but not in abdominal subcutaneous fat, suggesting that exogenous testosterone may inhibit LPL activity to a greater degree in intra-abdominal fat than abdominal subcutaneous fat. 36 Higher density of androgen receptors present in intra-abdominal fat 43 could partly explain why this fat depot is more responsive to testosterone replacement than subcutaneous fat and why there is IAF preferentially accumulated with lower serum testosterone. Visceral obesity is strongly associated with the metabolic consequences of insulin resistance, such as impaired glucose metabolism and unfavorable lipid pro®le. This association is also clearly demonstrated in our Japanese-American cohorts from earlier studies. 44, 45 It has been postulated that increased plasma FFA levels are associated with insulin resistance. 46, 47 By releasing directly into the portal system a greater amount of FFA from enhanced triglyceride breakdown, as a result of greater catecholaminestimulated andaor reduced insulin-inhibited lipolysis, visceral fat may contribute more profoundly to the metabolic abnormalities seen with the insulin resistance syndrome.
Many studies have shown an association between relative hypogonadism and insulin resistance. 14,15,19 ± 23 We also have previously shown that increased fasting insulin and C-peptide concentrations predicted IAF accumulation in Japanese Americans. 48 It is, therefore, not surprising that in the current analysis, both fasting insulin and C-peptide, as markers of insulin resistance and pancreatic b-cell function, respectively, were inversely correlated with total testosterone. However, the correlation between low testosterone and fasting insulin levels was diminished after adjusting for baseline IAF area. One possible explanation could be that IAF may be part of the pathway through which lower testosterone is related to insulin resistance. A similar observation was reported from 79 younger men in Quebec, Canada, in whom the authors found the close cross-sectional association between plasma testosterone and insulin levels (r À0.25) to be largely mediated by the concomitant variation in CT-measured visceral abdominal fat. 49 On the other hand, in another cross-sectional study of 23 healthy young Swedish men, Seidell et al observed that free testosterone levels remained independently correlated with fasting insulin (r À0.66 without adjustment), even after adjusting for CT-visceral fat area. 14 Haffner also reported a signi®cant correlation between free testosterone level and fasting insulin after adjusting for BMI and WHR. 23 Visceral adiposity was not assessed by CT in that study. No conclusion about the possible temporal relationship among testosterone, IAF and insulin resistance can be reached from these cross-sectional analyses. Overall, our results from the prospective analysis are in agreement with the temporal sequence of events proposed by Bjo Èrntorp: relative hypogonadism precedes central obesity, a notion that is supported by the in vivo effect of lowdose testosterone administration in reducing visceral fat and improving insulin sensitivity. 24 Additionally, our cross-sectional analysis also suggests, but does not con®rm, that testosterone may play a role in the insulin resistance syndrome by modulating the degree of visceral adiposity.
Since metabolism of androgens is closely linked to the protein-binding state of testosterone, several studies have also examined the importance of free testosterone and SHBG on obesity and DM prevalence. It appears that in moderately obese men (BMI`35), only total testosterone concentration was decreased, primarily as a result of reduced SHBG-binding capacity, and there was no reduction in the unbound or free testosterone fraction or any impairment in the pituitary ± gonadal axis. 13 In massively obese men (BMI b 40), however, the LH pulse amplitude was reduced, resulting in reduction in both total and free testosterone levels. 13 Therefore, the inconsistent ®ndings in the literature on free testosterone levels in obese men 14,21 ± 23 may have been due to admixture of both modestly and massively obese subjects. Moreover, free testosterone demonstrated weaker associations than total testosterone with indices of glucose metabolism in middle-aged healthy Finns. 15 Overall evidence, thus, would suggest that total testosterone is a better marker in examining relationships of sex steroids, obesity and glucose metabolism in men. Free testosterone levels were not assessed in our subjects due to the unavailability of a reliable assay at the time of data collection. However, since the mean BMI in our study population was 25.3 kgam 2 , their free testosterone concentrations were most likely in the normal range.
We did not measure SHBG concentrations and were not able to directly examine the relative roles of SHBG and bio-available testosterone levels in IAF accumulation or glucose metabolism. SHBG level, as an indirect index of bio-available fraction of sex steroids, has been proposed to be a better marker for androgen metabolism and insulin resistance. Similar to testosterone, decreased SHBG concentrations were also associated with higher CT-measured visceral fat areas in Swedish men 14 and with indices of glucose metabolism and WHR in Finns. 15 In the MRFIT trial, both low SHBG and testosterone levels predicted the development of type 2 DM in men. 16 However, in older Swedish men, low testosterone was a more signi®cant predictor of the onset of diabetes than low SHBG level, 17 and in Mexican-American males, SHBG level was not a predictor of type 2 DM at all. 50 Low testosterone in visceral fat accumulation EC Tsai et al Thus, SHBG does not clearly appear to be superior to testosterone level with regard to strength of association with measures of abnormal glucose metabolism.
The limitations of our study are several. Firstly, these observations in Japanese-American men may not apply to other ethnic populations. Nevertheless, our ®ndings are consistent with those found in Swedes, showing an association of testosterone and central obesity. Another limitation was that SHBG was not measured in our subjects. However, as discussed above, this is unlikely to have decreased our power to detect an association between androgenicity and central obesity. Finally, insulin sensitivity was assessed indirectly by fasting insulin level. As a marker, fasting insulin level correlated fairly well with insulin resistance quanti®ed by euglycemic hyperinsulinemic clamp, and is, therefore, a reasonable surrogate measure of insulin sensitivity in population studies. 51 Further studies are needed to con®rm our ®ndings in other populations. If con®rmed, it may be appropriate to examine the long-term effect of exogenous testosterone upon IAF in individuals with low normal testosterone levels.
